Excellent outcome following emergency deceased donor ABO-incompatible liver transplantation using rituximab and antigen specific immunoadsorption

References

• Tanabe M, Shimazu M, Wakabayashi G, et al. Intraportal infusion therapy as a novel approach to adult ABO-incompatible liver transplantation. Transplantation. 2002;73(12):1959–1961.
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Matsuno N, Iwamoto H, et al. Successful case of adult ABO-incompatible liver transplantation: beneficial effects of intrahepatic artery infusion therapy: a case report. Transplant Proc. 2004;36(8):2269–2273.
   PubMed Web of Science ®Google Scholar
• Usuda M, Fujimori K, Koyamada N, et al. Successful use of anti-CD20 monoclonal antibody (rituximab) for ABO-incompatible living-related liver transplantation. Transplantation. 2005;79(1):12–16.
   PubMed Web of Science ®Google Scholar
• Egawa H, Teramukai S, Haga H, et al. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology. 2008;47(1):143–152.
   PubMed Web of Science ®Google Scholar
• Egawa H, Teramukai S, Haga A, et al. Impact of rituximab desentitization on blood-type-incompatible adult living donor liver transplantation: a japanese multicenter study. Am J Transplant. 2014;14(1):102–114.
   PubMed Web of Science ®Google Scholar
• Kawagishi N, Ohuchi N, Satomi S. Current aspects of ABO-incompatible liver transplantation. Clin Case Rep and Rev. 2016;2(4):375–379.
   Google Scholar
• Song G-W, Lee S-G, Hwang S, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab. Am J Transplant. 2016;16(1):157–170.
   PubMed Web of Science ®Google Scholar
• Song G-W, Lee S-G, Hwang S, et al. Biliary stricture is the only concern in ABO-incompatible adult living donor liver transplantation in the rituximab era. J Hepatol. 2014;61(3):575–582.
   PubMed Web of Science ®Google Scholar
• Ikegami T, Yoshizumi T, Soejima Y, et al. Feasible usage of ABO incompatible grafts in living donor liver transplantation. Hepatobiliary Surg Nutr. 2016;5(2):91–97.
   PubMed Web of Science ®Google Scholar
• Park G-C, Song G-W, Moon D-B, et al. A review of current status of living donor liver transplantation. Hepatobiliary Surg Nutr. 2016;5(2):107–117.
   PubMed Web of Science ®Google Scholar
• Starzl TE, Koep LJ, Halgrimson CG, et al. Fifteen years of clinical liver transplantation. Gastroenterology. 1979;77(2):375–388.
   PubMed Web of Science ®Google Scholar
• Raut V, Uemoto S. Management of ABO-incompatible living-donor liver transplantation: past and present trends. Surg Today. 2011;41(3):317–322.
   PubMed Web of Science ®Google Scholar
• Farges O, Kalil AN, Samuel D, et al. The use of ABO-incompatible grafts in liver transplantation: a life saving procedure in highly selected patients. Transplantation. 1995;59(8):1124–1133.
   PubMed Web of Science ®Google Scholar
• Lo C-M, Shaked A, Busuttil RW. Risk factors for liver transplantation across the ABO barrier. Transplantation. 1994;58(5):543–547.
   PubMed Web of Science ®Google Scholar
• Gugenheim J, Samuel D, Reynes M, et al. Liver transplantation across ABO blood group barriers. Lancet. 1990;336(8714):519–523.
   PubMed Web of Science ®Google Scholar
• Gordon RD, Iwatsuki S, Esquivel O, et al. Liver transplantation across ABO blood groups. Surgery. 1986;100(2):342–348.
   PubMed Web of Science ®Google Scholar
• Demetris AJ, Jaffe R, Tzakis A, et al. Antibody-mediated rejection of human orthotopic liver allografts. Am J Pathol. 1988;132(3):489–502.
   PubMed Web of Science ®Google Scholar
• Reding R, Veyckemans F, de Ville de Goyet J, et al. ABO-incompatible orthotopic liver allografting in urgent indications. Surg Gynecol Obstet. 1992;174(1):59–63.
   PubMedGoogle Scholar
• Lee C-F, Cheng C-H, Wang Y-C, et al. Adult living donor liver transplantation across ABO-incompatibility. Medicine (Baltimore)). 2015;94(42):e1796.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kwon CHD, Joh J-W, et al. Case-matched comparison of ABO-incompatible and ABO-compatible living donor liver transplantation. Br J Surg. 2016;103(3):276–283.
   PubMed Web of Science ®Google Scholar
• Ghobrial RM, Freise CE, Trotter JF, A2ALL Study Group, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology. 2008;135(2):468–476.
   PubMed Web of Science ®Google Scholar
• Hanto DW, Fecteau AH, Alonso MH, et al. ABO-incompatible liver transplantation with no immunological graft losses using total plasma exchange, splenectomy, and quadruple immunosuppression: evidence for accommodation. Liver Transpl. 2003;9(1):22–30.
   PubMed Web of Science ®Google Scholar
• Mendes M, Ferreira AC, Ferreira A, et al. ABO-incompatible liver transplantation in acute liver failure: a single portuguese center study. Transplant Proc. 2013;45(3):1110–1115.
   PubMed Web of Science ®Google Scholar
• Thorsen T, Dahlgren US, Aandahl EM, et al. Liver transplantation with deceased ABO-incompatible donors is life-saving but associated with increased risk of rejection and post-transplant complications. Transpl Int. 2015;28(7):800–812.
   PubMed Web of Science ®Google Scholar
• Shen T, Lin B-Y, Jia J-J, et al. A modified protocol with rituximab and intravenous immunoglobulin in emergent ABO-incompatible liver transplantation for acute liver failure. Hepatobiliary Pancreat Dis Int. 2014;13(4):395–401.
   PubMed Web of Science ®Google Scholar
• Boberg KM, Foss A, Midtvedt K, et al. ABO-incompatible deceased donor liver transplantation with the use of antigen-specific immunoadsorption and anti-CD20 monoclonal antibody. Clin Transplant. 2006;20(2):265–268.
   PubMed Web of Science ®Google Scholar
• Nordén G, Briggs D, Cockwell P, et al. ABO-incompatible live donor renal transplantation using blood group a/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. Xenotransplantation. 2006;13(2):148–153.
   PubMed Web of Science ®Google Scholar
• Demetris A, Adams D, Bellamy C, et al. Update of the international banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology. 2000;31(3):792–799.
   PubMedGoogle Scholar
• Demetris A, Bellamy C, Hübscher SG, et al. 2016 Comprehensive update of the banff working group on liver allograft pathology: introduction of antibody-mediated rejection. Am J Transplant. 2016;16(10):2816–2835.
   PubMed Web of Science ®Google Scholar
• Roos FJM, Poley J-W, Polak WG, al.et al. Biliary complications after liver transplantation; recent developments in etiology, diagnosis and endoscopic treatment. Best Pract Res Clin Gastroenterol. 2017;31(2):227–235.
   PubMed Web of Science ®Google Scholar
• Villa NA, Harrison E. Management of biliary strictures after liver transplantation. Gastroenterol Hepatol (N Y). 2015;11(5):316–328.
   PubMedGoogle Scholar
• Lee HW, Suh K-S, Shin WS, et al. Classification and prognosis of intrahepatic biliary stricture after liver transplantation. Liver Transpl. 2007;13(12):1736–1742.
   PubMed Web of Science ®Google Scholar
• Ryu CH, Lee SK. Biliary strictures after liver transplantation. Gut Liver. 2011;5(2):133–142.
   PubMed Web of Science ®Google Scholar
• The Nordic Liver Transplant Registry (NLTR) annual report 2019. 2020. www.scandiatransplant.org.
   Google Scholar
• Kim SH, Park J, Park SJ. Impact of ABO-incompatibility on hepatic artery thrombosis in living donor liver transplantation. Ann Transl Med. 2019;7(22):625.
   PubMed Web of Science ®Google Scholar
• Yamamoto H, Uchida K, Kawabata S, et al. Feasibility of monotherapy by rituximab without additional desensitization in ABO-incompatible Living-Donor Liver Transplantation. Transplantation. 2018;102(1):97–104.
   PubMed Web of Science ®Google Scholar
• Lee EC, Kim SH, Shim JR, et al. A comparison of desensitization methods: Rituximab with/without plasmapheresis in ABO-incompatible living donor liver transplantation. Hepatobiliary Pancreat Dis Int. 2018;17(2):119–126.
   PubMed Web of Science ®Google Scholar
• Tydén G, Kumlien G, Genberg H, et al. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant. 2005;5(1):145–148.
   PubMed Web of Science ®Google Scholar
• Puisset F, White-Koning M, Kamar N, et al. Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol. 2013;76(5):734–740.
   PubMed Web of Science ®Google Scholar
• Tan EXX, Wang MX, Pang J, et al. Plasma exchange in patients with acute and acute-on-chronic liver failure: a systematic review. WJG. 2020;26(2):219–245.
   PubMed Web of Science ®Google Scholar
• Skogsberg U, Breimer ME, Friman S, et al. Successful ABO-incompatible liver transplantation using A2 donors. Transplant Proc. 2006;38(8):2667–2670.
   PubMed Web of Science ®Google Scholar
• Kluger MD, Guarrera JV, Olsen SK, et al. Safety of blood group A2-to-O liver transplantation: an analysis of the united network of organ Sharing database. Transplantation. 2012;94(5):526–531.
   PubMed Web of Science ®Google Scholar
• Breimer M, Samuelsson BE. The specific distribution of glycolipid-based blood group a antigens in human kidney related to A1/A2, Lewis, and secretor status of single individuals. A possible molecular explanation for the successful transplantation of A2 kidneys into O recipients. Transplantation. 1986;42(1):88–91.
   PubMed Web of Science ®Google Scholar
• Breimer ME, Mölne J, Nordén G, et al. Blood group a and B antigen expression in human kidneys correlated to A1/A2/B, Lewis, and secretor status. Transplantation. 2006;82(4):479–485.
   PubMed Web of Science ®Google Scholar
• Moreau R, Jalan R, Gines P, et al. Acute-on-chronic liver failure is a distinct syndrome that developed in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426–1437.
   PubMed Web of Science ®Google Scholar